Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial

• Published in: The Nigerian postgraduate medical journal Vol. 20; no. 4; pp. 272 - 281
• Main Authors: Odusanya, O O, Kuyinu, Y A, Kehinde, O A, Francois, N, Yarzabal, J P, Moreira, M, Borys, D, Schuerman, L
• Format: Journal Article
• Language: English
• Published: Nigeria Wolters Kluwer Medknow Publications 01-12-2013
• Subjects: Antibodies, Bacterial - blood; Bacterial Proteins - immunology; Bordetella pertussis - immunology; Carrier Proteins - immunology; Cohort Studies; Diphtheria Toxin - immunology; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage; Female; Haemophilus Vaccines - administration & dosage; Hepatitis B Surface Antigens - immunology; Hepatitis B Vaccines - administration & dosage; Humans; Immunoglobulin D - immunology; Immunoglobulin G - blood; Infant; Lipoproteins - immunology; Male; Nigeria; Pneumococcal Vaccines - administration & dosage; Pneumococcal Vaccines - adverse effects; Pneumococcal Vaccines - immunology; Poliovirus Vaccine, Oral - administration & dosage; Polysaccharides - immunology; Streptococcus pneumoniae - immunology; Tetanus Toxin - immunology; Nigeria
• ISSN: 1117-1936; 2468-6875
• DOI: 10.4103/1117-1936.164603

The immunogenicity, reactogenicity and safety of the 10- valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) were evaluated in a cohort of Nigerian infants included in a study conducted in Mali and Nigeria (ClinicalTrials.gov identifier: NCT00678301).
In this open, randomised, controlled study, 119 healthy infants received combined diphtheria-tetanus-whole-cell pertussis-hepatitis B/ Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) and oral poliovirus vaccine (OPV) co-administered with PHiD-CV (PHiD-CV group) or without PHiD-CV (control group) at 6-10-14 weeks of age. Pneumococcal antibody responses and opsonophagocytic activity were measured and adverse events were recorded.
One month post-dose 3, for each of the vaccine pneumococcal serotypes, e"90.1% of PHiD-CV recipients had an antibody concentration e"0.2 ug/mL compared to < 9 % (except for serotypes 14 [32.4%] and 19F [27.8%]) in the control group. For each of the vaccine pneumococcal serotypes, e"90.6% of infants in the PHiD-CV group had an OPA titre e"8, compared to % 18% (except for serotype 7F [60.0%]) in the control group. Anti-protein D antibody geometric mean antibody concentrations were 2949.7 EL.U/mL in the PHiD-CV group and 68.9 EL.U/mL in the control group. For each DTPw-HBV/Hib antigen antibody seroprotection/seropositivity rates were e"94.4%. Tolerability was generally comparable between the PHiD-CV and control vaccination groups.
PHiD-CV co-administered with routine vaccines was immunogenic for all vaccine pneumococcal serotypes and protein D in Nigerian infants. Vaccine tolerability was generally comparable between the PHiD-CV and control groups. These results suggest PHiD-CV can be co-administered with other vaccines included in the National Programme on Immunisation.